Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PER2 | O15055 | 7/20 | 0.40 |
| ▸ | CRY1 | Q16526 | 7/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 7/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19970012 | 0.86 | HTR3A (0.55) | HTR3AKCNH2HTR2AHTR7HTR6 | |
| SCHEMBL17176277 | 0.85 | HTR3A (0.57) | HTR3AKCNH2HTR6PER2CRY1 | |
| SCHEMBL15556917 | 0.85 | HTR3A (0.57) | HTR3AHTR6PER2CRY1CRY2 | |
| SCHEMBL17170593 | 0.81 | HTR3A (0.56) | HTR3AHTR6PER2CRY1CRY2 | |
| SCHEMBL19068172 | 0.80 | KMT2A (0.57) | HTR3AHTR6CNR1 | |
| SCHEMBL15558080 | 0.78 | HTR3A (0.59) | HTR3APER2CRY1CRY2 | |
| SCHEMBL8253688 | 0.76 | HTR3A (0.46) | HTR3AHTR2AHTR7HTR6PER2 | |
| SCHEMBL19969961 | 0.76 | HTR3A (0.57) | HTR3AKCNH2CNR1CNR2 | |
| SCHEMBL14831344 | 0.75 | HTR3A (0.51) | HTR3AHTR2AHTR7HTR6PER2 | |
| SCHEMBL15730221 | 0.75 | HTR6 (0.46) | HTR3AKCNH2HTR6PER2CRY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885KCNH2 1086/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.